Product How it works Pricing Blog FAQ About Contact
Connect Biopharma

Connect Biopharma (NASDAQ: CNTB) revenue

Connect Biopharma reported revenue of $0.1m for fiscal 2025, 99.8% less than in fiscal 2024 ($26.0m).

Connect Biopharma's best year of the last 3 was fiscal 2024. The biggest drop was in fiscal 2025, −99.8%.

Revenue, in millions of US dollars0.0202326.020240.12025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$0.1m−99.8%−$58.1m−90,740.6%
2024$26.0m—−$22.5m−86.2%
2023$0.0m—−$69.1m—

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Connect Biopharma revenue compared with its sector

By revenue for its latest fiscal year, Connect Biopharma ranks 399th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Connect Biopharma, −99.8%.

RankCompanyRevenueRevenue growth
397thProKidney$0.9m1,075.0%
398thPulse Biosciences$0.4m—
399thConnect Biopharma$0.1m−99.8%
400thAvalo Therapeutics$0.1m−86.6%
401stAltimmune$0.0m105.0%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Connect Biopharma

How much revenue did Connect Biopharma make in fiscal 2025?
Connect Biopharma reported revenue of $0.1m for fiscal 2025, compared with $26.0m in fiscal 2024.
What was the best year for revenue at Connect Biopharma?
Of its last 3 fiscal years, fiscal 2024, with $26.0m.
Where does Connect Biopharma rank in its sector by revenue?
It ranks 399th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Connect Biopharma come from?
From the annual report (Form 10-K) that Connect Biopharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Connect Biopharma files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023. More on Connect Biopharma: the Connect Biopharma page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.